Precision Oncology 2026: New Horizons in Advanced Lung Cancer

In modern oncology, a diagnosis of advanced lung cancer (NSCLC/SCLC) is no longer a static verdict, but the beginning of a complex molecular investigation. At Hallwang Clinic, treatment is defined by access to next-generation immunotherapies and evidence-based off-label strategies.

Contemporary cancer research offers a broad spectrum of therapeutic approaches that extend far beyond what is established as standard in routine clinical practice. Guideline-based treatments are designed around large patient populations and therefore only partially reflect the biological complexity of an individual tumor.

The Hallwang Clinic deliberately pursues an expanded approach: in-depth molecular diagnostics, internationally informed treatment pathways, and scientifically grounded off-label strategies—integrated into a precision-oncology model that begins where standard protocols reach their limits.

Depth of Diagnostics: Multi-Omics Instead of Standard Panels

A conventional biopsy is no longer sufficient to fully capture the dynamic complexity of metastatic disease. Through whole-exome sequencing and RNA sequencing, we identify complex gene fusions and splice variants beyond classical mutation panels—including previously hidden resistance markers. Complementary epigenetic profiling reveals methylation patterns and uncovers silent resistance mechanisms that remain invisible in standard sequencing approaches.

In addition, single-cell analysis decodes intratumoral heterogeneity at the cellular level. Often, it is individual resistant clones that ultimately determine therapeutic outcomes. All data streams are integrated into a dynamic tumor model that reflects clonal evolution in real time—forming the basis for adaptive treatment strategies designed to anticipate resistance before it becomes clinically apparent.

Targeted Therapies 2.0: Proactively Overcoming Resistance

Precision medicine has opened new therapeutic targets in lung cancer that extend far beyond established first-line treatments. Our approach focuses on proactively overcoming resistance mechanisms—before they become clinically relevant. This includes the use of next-generation EGFR inhibitors and bispecific antibodies following treatment failure, as well as targeted KRAS inhibition for mutations that were previously considered difficult to treat. In addition, antibody–drug conjugates (ADCs) play a central role—delivering highly potent agents directly into tumor cells with surgical precision, maximizing efficacy while minimizing systemic toxicity.

Immuno-Oncology 3.0: Activating the “Cold” Tumor

Classical checkpoint inhibition now often represents only the starting point of immunotherapy. To reach patients who do not respond to standard approaches, we target additional immune checkpoints—such as LAG-3, TIGIT, or VISTA—to more comprehensively overcome T-cell exhaustion.

At the same time, we develop personalized tumor vaccines based on individual neoantigens, enabling the immune system to recognize and attack the tumor with high specificity. A critical component is the active modulation of the tumor microenvironment. By targeting tumor-associated macrophages and the extracellular matrix, we render previously immunologically “cold” tumors accessible to immune cells—fundamentally enhancing the effectiveness of immunotherapy.

Dynamic Therapy Management Through Liquid Biopsy

Tumors evolve continuously under the selective pressure of therapy. Conventional imaging often lags behind this biological dynamic. For this reason, we use highly sensitive liquid biopsy (ctDNA) as a standard tool in treatment monitoring.

By analyzing circulating tumor DNA, we are able to detect emerging resistance mechanisms long before they become visible on imaging, continuously assess molecular treatment response, and adapt therapy in real time as tumor activity changes. This enables a consistently data-driven approach—proactive rather than reactive.

Our Clinical Commitment

The Hallwang Clinic bridges the gap between leading international research and individualized patient care. Through access to compassionate use programs and scientifically grounded off-label combinations, we open therapeutic pathways that extend far beyond the scope of national standard care. Every treatment decision is guided by the molecular reality of the individual tumor—precise, adaptive, and uncompromising.